PABPC1 expression in papillary renal cell carcinoma and its significance for survival outcomes

This study examines the expression pattern and prognostic relevance of PABPC1 in papillary renal cell carcinoma (pRCC) to evaluate its potential as a clinical outcome biomarker.

In papillary renal cell carcinoma (pRCC), mRNA expression levels of PABPC1 were analyzed by comparing tumor (n = 290)and normal tissues (n = 32)using the GSCALite and UALCAN databases. Immune checkpoint expression in KIRP was evaluated with TCGA transcriptomic data.Survival analyses via GSCALite assessed the relationship between PABPC1 expression levels(144 high,145 low) and patient outcomes.Correlations between PABPC1 and clinical/pathological stages were examined for prognostic value.Validation involved HE and IHC staining on 7 clinical samples, with quantitative assessment of PABPC1 protein expression in papillary renal cell carcinoma (pRCC) tissues.

An upsurge in PABPC1 was detected in papillary renal cell carcinoma (pRCC) during the study.ThereisasignificantassociationbetweenhighPABPC1 expression in patients and reduced overall survival (OS), progression-free survival (PFS), disease-specific survival (DSS), and disease-free interval (DFI) compared to lowexpression,with Log-rank P-values of 4.1e-05, 3.2e-06, 2.4e-07, and 0.00027, respectively, suggesting a poorer prognosis for KIRP patients.Moreover, the mRNA expression level of PABPC1 gradually increased with the progression of clinical and pathological stages.PD1/PDL1 inhibitors could enhance the prognosis of papillary renal cell carcinoma.

PABPC1 could serve as a potential prognostic biomarker for individuals with KIRP.